Laboratorios Farmaceuticos Rovi revenue and financials
€58.85Change from previous close: +1.20%Absolute change: +€0.70
In the fiscal year ended December 2025, Laboratorios Farmaceuticos Rovi reported revenue of €743.48M (−2.65% year over year). Net income was €140.44M, a net margin of 18.9%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- −2.65%
- 2025 vs 2024
- Net income growth
- +2.60%
- 2025 vs 2024
- Net margin
- 18.9%
- 2024: 17.9%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Total assets | 1,127 | 926 | 956 | 922 | 870 | — |
| Current assets | 568 | 539 | 567 | 559 | 516 | — |
| Cash and equivalents | 127 | 97.4 | 98.0 | 49.3 | 46.1 | — |
| Short-term investments | 1.1 | — | — | — | 1.5 | — |
| Inventory | 273 | 274 | 288 | 315 | 328 | — |
| Net property, plant and equipment | 486 | 329 | 331 | 305 | 294 | — |
| Goodwill | 2.7 | 2.7 | 2.7 | — | 2.7 | — |
| Other intangible assets | 33.0 | 32.4 | 33.2 | — | 33.0 | — |
| Long-term investments | 19.3 | 19.2 | 19.2 | 19.1 | 19.0 | — |
| Current liabilities | 277 | 148 | 181 | 185 | 187 | — |
| Accounts payable | 84.0 | 75.8 | 81.8 | 102 | 64.6 | — |
| Long-term debt | — | — | 83.9 | — | — | — |
| Total debt | 108 | 114 | 122 | 124 | 129 | — |
| Total liabilities | 410 | 240 | 280 | 289 | 295 | — |
| Total equity (incl. minority) | 717 | 687 | 675 | 633 | 575 | — |
| Retained earnings | 613 | 589 | 578 | 535 | 477 | — |
| Minority interest | 16.4 | 12.8 | 11.0 | 11.1 | 11.1 | — |